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Introduction
Benzodiazepines and their derivatives are routinely prescribed for a variety of medical conditions as anxiolytic, anti-insomnia and anti-convulsant drugs, acting on the gammaaminobutyric acid type A (GABA A ) receptor [1, 2] . The endogenous neurotransmitter for the GABA A receptor is gamma-aminobutyric acid (GABA), the binding of which reduces the excitability of the cell [3] . Benzodiazepines potentiate the response of the GABA A receptor to GABA which results in far less cellular excitability which, in physiological terms, results in sedation and relaxation [1] .
In these circumstances benzodiazepines are medically beneficial by alleviating stress and agitation in patients through their anxiolytic effects. However, as a result of their psychoactive effects, benzodiazepines have a long history of abuse and are often illicitly obtained [4] [5] [6] . In more recent years a steady stream of benzodiazepines have appeared on the illicit market that have either been newly-synthesised or are licensed as prescription drugs in another country but not in the home country [7] [8] [9] [10] . These are termed 'new psychoactive substances' (NPS) [11, 12] . The majority of these emerging benzodiazepines have not undergone standard pharmaceutical trials and can be quite variant in their effects and potentially dangerous in their activity [13] . Although relatively safe when used as medically prescribed, concurrent use of benzodiazepines and opioids (either prescribed or abused) can lead to respiratory depression and death [4, 14, 15] . When benzodiazepines are not carefully prescribed and monitored, they can cause a variety of side effects including tolerance and dependency if taken long-term and sudden withdrawal can cause medical problems including anxiety and insomnia [16] [17] [18] . These NPS benzodiazepines have already been reported in a number of overdose cases, driving under the influence of drugs (DUID) cases and hospital admissions [8, [19] [20] [21] [22] . The lack of control and safety over these illicit benzodiazepines is a
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prevalent issue and it is likely that it will become an even more worrying trend as their misuse continues to rise.
Benzodiazepines are a diverse group of psychoactive compounds with a central structural component consisting of a benzene ring and a diazepine ring (Figure 1) . A whole host of derivatives exist which include triazolobenzodiazepines, thienotriazolobenzodiazepines and imidazobenzodiazepines (see Supplementary Information Figure S1 and Table S1 ).
Quantitative structure-activity relationship (QSAR) models attempt to correlate molecular structure to biological activity, often using a variety of molecular descriptors such as physiochemical, topological, electronic and steric properties [23] . Typically, a set of compounds whose biological activity is known is used to create a 'training' dataset and a model. This model can then be used to predict the unknown biological activity of compounds with a similar structure or to explore the structural features that are important for the specific biological activity in question. QSAR has been extensively used for a variety of reasons such as compound development in the pharmaceutical industry and the pharmacological interpretation of drug-related deaths [24] [25] [26] . In terms of applications towards new psychoactive substances, the predictive power of QSAR has been mainly applied to cannabinoid binding to the CB 1 and CB 2 receptors [27] [28] [29] but has also been used to examine the biological activity of hallucinogenic phenylalkylamines [30] , the binding of phenylalkylamines, tryptamines and LSD to the 5-HT 2A receptor [31] and methcathinone selectivity for dopamine (DAT), norepinephrine (NAT) and serotonin transporters (SERT) [32] . Currently, the majority of novel benzodiazepines have not been analysed to determine their physicochemical and biological properties as this would require a substantial investment in both time and money. It is for this reason that a fast, yet economical method to predict their properties is desirable.
QSAR has previously been applied to benzodiazepines to predict bioavailability, absorption rate, clearance, half-life and volume of distribution for a group of benzodiazepines. This study included phenazepam [33] , a benzodiazepine that appeared as an NPS in 2007 [34] .
Other benzodiazepines (such as etaziolam) only appeared as new psychoactive substances in the years following the publication of this study. Furthermore, the application of a QSAR methodology has been used for modelling post-mortem redistribution of benzodiazepines where a good model was obtained (R 2 = 0.98) in which energy, ionisation and molecular size were found to exert significant impact [35] . Quantitative structure-toxicity relationships (QSTR) have been used to correlate the toxicity of benzodiazepines to their structure in an attempt to predict the toxicity of these compounds [36] . More recently, a study reported the use of QSTR whereby it was concluded that it is possible to identify structural fragments responsible for toxicity (the presence of amine and hydrazone substitutions as well as saturated heterocyclic ring systems resulted in a greater toxicity) and potentially use this information to create new, less toxic benzodiazepines for medical use [37] .
Various QSAR models have been used to correlate benzodiazepine structure to GABA A receptor binding and tease apart the complex relationship between various substituents and their effect on activity [38] [39] [40] [41] [42] [43] although none have specifically attempted to predict binding values for benzodiazepines that are new psychoactive substances.
In this study we focus on the relationship between the structure of characterised benzodiazepines and GABA A receptor binding, expressed as the logarithm of the reciprocal of concentration (log 1/c) where c is the molar inhibitory concentration (IC 50 ) required to displace 50 % of [3H]-diazepam from rat cerebral cortex synaptosomal preparations [41] .
The purpose of this work is to create a QSAR model that can be used to predict the potential biological activity of the newly-emerging benzodiazepines to help understand, and therefore minimise their harmful potential in a faster time scale compared with in vitro/in vivo testing.

Methods and Materials
Selection of the dataset
The binding data for the benzodiazepines was used as obtained from the literature, experimentally determined using spectrometric measurements of [3H]-diazepam displacement [44] . Benzodiazepines were selected from four categories; 1,4-benzodiazepines, triazolobenzodiazepines, imidazobenzodiazepines and thienotriazolobenzodiazepines.
Benzodiazepines that did not have definitive binding values (i.e. listed values were simply stated as >1000 or >5000) were excluded. For simplicity benzodiazepines with atypical atoms or substituents (e.g. Ro 07-9238 which contained a sodium atom and Ro 05-5065 which contained a naphthalene ring) were also excluded. Benzodiazepines that also had atypical substitutions (i.e. positions R6, R8 and R9 from Figure 1 which are not found in medicallyused benzodiazepines or indeed those that are new psychoactive substances) were also excluded. In total, 88 benzodiazepines were selected for the training dataset.
QSAR/Software and Data Analysis Method
The 88 benzodiazepines were converted from SMILES to 3D structures based on Merck Molecular Force Field (MMFF) atom type and force field optimisation. These compounds were then aligned by common substructure and confirmation to Ro 05-306. Subsequently, the aligned compounds were clustered by Atomic Property Fields (APF) to identify benzodiazepines with poor alignment. The APF method, designed by MolSoft, uses the assignment of a 3D pharmacophore potential on a continuously distributed grid using physiochemical properties of the selected compound(s) to classify or superimpose compounds.
These properties include: hydrogen bond donors, acceptors, Sp2 hybridisation, lipophilicity, size, electropositivity/negativity and charge [45, 46] . Poorly aligned benzodiazepines identified by APF clustering were subjected to re-alignment using APF-based flexible
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superimposition. At this point, 10 benzodiazepines with poor alignment were removed to improve model accuracy. (Supplementary Information Table 1S ).
From the remaining 78 aligned compounds, 9 compounds were selected using a random number generator based on atmospheric noise. These compounds were removed from the training set and used for final model validation. The residual 69 compounds were used as the training set to build a 3D QSAR model, as shown in Figure 2 .
The APF 3D QSAR method was used where, for each of the 69 aligned compounds, the seven physicochemical properties were calculated and pooled together. Based on the activity data obtained from literature and the 3D aligned structures for the known compounds, weighted contributions for each APF component were obtained to allow quantitative activity predictions for unknown compounds. The optimal weight distributions were assigned by partial least-squares (PLS) methodology, where the optimal number of latent vectors for PLS was established by leave-one-out cross-validation on the training set. Then the weighted contributions were added together. The 9 compounds for validation and unknown compounds were assigned predicted binding values by calculating their fit within the combined QSAR APF. Any unknown benzodiazepines were subjected to the conversion and alignment protocol before predicted binding data was obtained. The above steps were conducted using Molsoft's ICM Pro software [47] .
Further analysis of the PLS model fragment contributions from the 69 compounds was conducted using SPCI software. Here, a 2D QSAR model was built using the same PLS methodology as above. Additionally, a consensus model was created from averaging the predictions of PLS, gradient boosting, support vector machine and random forest modelling methods. The compounds were then subjected to automatic fragmentation and contribution calculations, which resulted in information on 11 key contributing groups [48] . Using Ligand
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Scout with default settings, four ligand-based pharmacophore models were created using compounds with binding values of 6.0-9.0, 7.0-9.0, 8.0-9.0 and 8.5-9.0, as exemplified in Ten benzodiazepines that had the highest predicted binding values were docked into a modelled GABA A5 receptor using ICM software. The GABA A5 receptor model was generated by homology modelling, using the crystal structure of a human GABA(A)R-beta3
homopentamer (PDB id 4COF) as a template. A pre-defined binding site containing cocrystallised benzodiazepine is already present in the template, which was retained in the final model. Modeller software was used to generate the homology models [49] . The final chosen model was energy minimized using the ACEMD software [50] . The stereochemistry was checked using Procheck and ProSA software [51, 52] . The benzodiazepine in the allosteric binding site on the GABA A5 receptor was used as a chemical template to dock NPSbenzodiazepines and the best-scoring conformations were analysed.
The distances between principle physiochemical properties and their weights in the pharmacophore model were calculated using the software LigandScout [53] .
Results and Discussion
The data that was used to create the QSAR model (i.e. benzodiazepine structural substitutions and experimentally-observed binding values) is provided in the Supplementary Information (Table S1) .
From the pharmacophore model visualised in Figure 3 for highly bound benzodiazepines (log 1/c of 8.0 -9.0), it is evident that important binding features for the benzodiazepines were the positioning of two H-bond acceptors, two aromatic rings and a hydrophobic group all with weights of 1.0.
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The predicted binding values are not presented here but are listed in Supplementary Information (Table S1 ). They can be visualised in Figure 4 as a plot of the observed binding value versus the predicted binding value.
Nine compounds were selected at random from the QSAR training set and their binding values estimated using the model as a system of internal validation. These estimated values
were then compared to the experimental binding values ( Figure 5 ). 
PLS 2D QSAR modelling [48] . However, the consensus from multiple modelling methods improves the predictive power of the 2D QSAR model. Additionally, as experimental errors in the training set are amplified both by the logarithmic scale and when calculating the weighted contributions, consistency and accuracy in the initial experimental values are essential for a strong QSAR model. Ideally, further improvements to the model could be made by using a larger training dataset with lower diversity yet this cannot be achievable as a consequence of limitations on literature data available.
From these docking studies with the modelled GABA A5 receptor it can be seen that they only partially occupy the available volume at the allosteric binding site (exemplified in Figure 6 for flunitrazolam). From the ten compounds that had the greatest binding affinity, four had non-bonded interactions with the T80 region within the receptor, two had non-bonded interactions with the K182 and S231 regions respectively. There were also stacking interactions with the Y96 region for four of the compounds. Therefore the possibility is that the binding is not completely optimal for these benzodiazepines and that with a modified chemical structure, a greater binding affinity could be theoretically possible. The reality exists that a benzodiazepine with an optimised binding affinity could emerge onto the illicit drugs market and could potentially (but not necessarily) exhibit a greater potency.
The 10 compounds with the greatest binding affinity for the receptor are listed in Table 6 (lower scores indicate a greater binding effect).
There are 35 benzodiazepines and their derivatives currently subject to international control, 30 of these compounds had binding values listed in the original source [44] . The average log 1/c value for these 30 controlled compounds was 7.57. Out of these compounds, 43 % (13 out of 30) had a log 1/c value that was greater than 8.00. The average log 1/c value for the whole training dataset was 7.81 and 48 % of the compounds (33 out of 69) had a log 1/c value that was greater than 8.00. These values are fairly similar, however when comparing the results of ACCEPTED MANUSCRIPT position of the phenyl ring are known to exhibit strong steric repulsion at the GABA A receptor interface and therefore compound binding is severely inhibited [40] [57]. 4-chlorodiazepam is an outlier and atypical benzodiazepine as it does not act upon the GABA A receptor; instead exerting its pharmacological effects through the translocator protein 18 kDa (TSPO), previously known as the peripheral benzodiazepine receptor [58, 59] .
The 
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Highlights  There is a deficiency in the pharmacological data available for new benzodiazepines.
 69 benzodiazepines were used to develop a quantitative structure-activity relationship (QSAR).
 The resultant QSAR model returned an R 2 value of 0.90.
 This model will allow rapid prediction of the pharmacology of emerging benzodiazepines.
